A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.

NCT Number	NCT07483073
Lead Sponsor	Eli Lilly and Company
Conditions	Colitis, Ulcerative, Crohn Disease
Enrollment	60 participants
Start Date	2026-05-04
Primary Completion	2027-06 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-06